These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35339117)

  • 1. Outcomes of long-term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review.
    El Alayli A; Brignardello Petersen R; Husainat NM; Kalot MA; Aljabiri Y; Turkmani H; Britt A; El-Khechen H; Shahid S; Roller J; Motaghi S; Mansour R; Tosetto A; Abdul-Kadir R; Laffan M; Weyand A; Leebeek FWG; Arapshian A; Kouides P; James P; Connell NT; Flood VH; Mustafa RA
    Haemophilia; 2022 May; 28(3):373-387. PubMed ID: 35339117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network.
    Abshire T; Cox-Gill J; Kempton CL; Leebeek FW; Carcao M; Kouides P; Donfield S; Berntorp E
    J Thromb Haemost; 2015 Sep; 13(9):1585-9. PubMed ID: 25930155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network.
    Holm E; Abshire TC; Bowen J; Álvarez MT; Bolton-Maggs P; Carcao M; Federici AB; Gill JC; Halimeh S; Kempton C; Key NS; Kouides P; Lail A; Landorph A; Leebeek F; Makris M; Mannucci P; Mauser-Bunschoten EP; Nugent D; Valentino LA; Winikoff R; Berntorp E
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):383-8. PubMed ID: 25688461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis of bleeding episodes in patients with von Willebrand's disease.
    Federici AB
    Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s26-32. PubMed ID: 19105507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network.
    Holm E; Carlsson KS; Lövdahl S; Lail AE; Abshire TC; Berntorp E
    Haemophilia; 2018 Jul; 24(4):628-633. PubMed ID: 29626372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.
    Peyvandi F; Castaman G; Gresele P; De Cristofaro R; Schinco P; Bertomoro A; Morfini M; Gamba G; Barillari G; Jiménez-Yuste V; Königs C; Iorio A; Federici AB
    Blood Transfus; 2019 Sep; 17(5):391-398. PubMed ID: 30747707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, economic, and health-related quality of life burden associated with von Willebrand disease in adults and children: Systematic and targeted literature reviews.
    Castaman G; Katsarou O; Jansen N; Santos S; Escolar G; Berntorp E
    Haemophilia; 2023 Mar; 29(2):411-422. PubMed ID: 36097135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating the success of prophylaxis in haemophilia to von Willebrand disease.
    Miesbach W; Berntorp E
    Thromb Res; 2021 Mar; 199():67-74. PubMed ID: 33445035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN).
    Abshire TC; Federici AB; Alvárez MT; Bowen J; Carcao MD; Cox Gill J; Key NS; Kouides PA; Kurnik K; Lail AE; Leebeek FW; Makris M; Mannucci PM; Winikoff R; Berntorp E;
    Haemophilia; 2013 Jan; 19(1):76-81. PubMed ID: 22823000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature.
    Brignardello-Petersen R; El Alayli A; Husainat N; Kalot M; Shahid S; Aljabirii Y; Britt A; Alturkmani H; El-Khechen H; Motaghi S; Roller J; Dimassi A; Abughanimeh O; Madoukh B; Arapshian A; Grow JM; Kouides P; Laffan M; Leebeek FWG; O'Brien SH; Tosetto A; James PD; Connell NT; Flood V; Mustafa RA
    Blood Adv; 2022 Jan; 6(1):121-128. PubMed ID: 34654053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of prophylaxis in the management of von Willebrand disease: today and tomorrow.
    Abshire T
    Thromb Res; 2009 Nov; 124 Suppl 1():S15-9. PubMed ID: 19944256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Efficacy and Safety of Fanhdi
    Jiménez-Yuste V; Alvarez-Román MT; Palomo Bravo Á; Galmes BJ; Nieto Hernández MDM; Benítez Hidalgo O; Marzo Alonso C; Pérez González NF; Coll J; Núñez R; Carrasco M; García Candel F; Gonzalez-Porras JR; Hernández García C; Varó Castro MJ; Mir R
    Clin Appl Thromb Hemost; 2022; 28():10760296221074348. PubMed ID: 35108125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
    van Galen KP; Engelen ET; Mauser-Bunschoten EP; van Es RJ; Schutgens RE
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD011385. PubMed ID: 31002742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Von Willebrand disease.
    Berntorp E
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S34-6. PubMed ID: 23109385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
    van Galen KP; Engelen ET; Mauser-Bunschoten EP; van Es RJ; Schutgens RE
    Cochrane Database Syst Rev; 2015 Dec; (12):CD011385. PubMed ID: 26704192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
    Federici AB
    Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis.
    Kalot MA; Husainat N; El Alayli A; Abughanimeh O; Diab O; Tayiem S; Madoukh B; Dimassi AB; Qureini A; Ameer B; Eikenboom JCJ; Giraud N; McLintock C; McRae S; Montgomery RR; O'Donnell JS; Scappe N; Sidonio RF; Brignardello-Petersen R; Flood VH; Connell NT; James PD; Mustafa RA
    Blood Adv; 2022 Jan; 6(1):62-71. PubMed ID: 34610118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature.
    Brignardello-Petersen R; El Alayli A; Husainat N; Kalot MA; Shahid S; Aljabirii Y; Britt A; Alturkmani H; El-Khechen H; Motaghi S; Roller J; Abdul-Kadir R; Couper S; Kouides P; Lavin M; Ozelo MC; Weyand A; James PD; Connell NT; Flood VH; Mustafa RA
    Blood Adv; 2022 Jan; 6(1):228-237. PubMed ID: 34673921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.